Naresh Chouhan, Intron Health principal, joins 'Squawk Box' to discuss why he's downgrading Novo Nordisk from buy to sell and slashing the target price. Got a confidential news tip? We want to hear ...
22.08.2022 / 07:00 CET/CEST Intron Health today published its first independent research report on Xlife Sciences (SIX: XLS). The coverage starts with a «Buy» rating and a target price of CHF 47.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results